2,892 results match your criteria Breast[Journal]


A multi-stakeholder approach in optimising patients' needs in the benefit assessment process of new metastatic breast cancer treatments.

Breast 2020 May 10;52:78-87. Epub 2020 May 10.

Canadian Breast Cancer Network, Ottawa, ON, Canada.

There is a growing understanding as science evolves that different cancer types require different approaches to treatment evaluation, especially in the metastatic stages. The introduction of new metastatic breast cancer (MBC) treatments may be hindered by several elements, including the availability of relevant evidence related to disease-specific outcomes, the benefit assessment process around the evaluation of the clinical benefit and the patients' need of new treatments. The Steering Committee (SC) found that not all issues relevant to MBC patients are consistently considered in the current benefit assessment process of new treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.04.011DOI Listing

Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab.

Breast 2020 May 16;52:71-77. Epub 2020 May 16.

Institute for Medical Technology Assessment, Erasmus University Rotterdam, the Netherlands; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, the Netherlands.

Objective: To investigate resource use and time investments of healthcare professionals, patients and their family and to compare healthcare and societal costs of one single hospital-based and one single home-based subcutaneous administration of trastuzumab in The Netherlands.

Method: We conducted a bottom-up micro-costing study. Patients diagnosed with HER2+ early or metastatic breast cancer were recruited in four Dutch hospitals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.05.001DOI Listing

Late effects of adjuvant chemotherapy adumbrate dormancy complexity in breast cancer.

Breast 2020 May 8;52:64-70. Epub 2020 May 8.

Unit of Medical Statistics, Biometry and Bioinformatics "Giulio A. Maccacaro", Department of Clinical Sciences and Community Health, University of Milan Campus Cascina Rosa, Fondazione IRCCS Istituto Nazionale Tumouri, Milan, Italy. Electronic address:

Background: Dormant avascular micrometastases and single, or small groups of, non-proliferating cells are currently assumed to explain the multipeak dynamics of distant metastases (DM) following primary breast cancer surgical removal.

Methods: The hazard rate pattern for DM was analysed in 1518 premenopausal node-positive patients, enrolled in a series of randomized clinical trials on early breast cancer, which were carried out in Italy and Belgium. Patients underwent surgery alone (n = 397) or surgery plus adjuvant chemotherapy (n = 1121) and the minimal follow up was 15 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.05.002DOI Listing

Fertility in Breast Cancer Survivors in the Middle East: A Retrospective Study.

Breast 2020 Apr 29;52:58-63. Epub 2020 Apr 29.

Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.

Introduction: By the time they complete breast cancer therapy, many young patients are still of childbearing age. We aim to estimate the incidence of pregnancies in women who completed treatment and examine the percentage of patients who received fertility counseling before initiation of therapy.

Material And Methods: Electronic health records of breast cancer patients between 2008 and 2014 at AUBMC were screened for exclusion criteria of having metastatic disease or known infertility, still receiving therapy, and being above 42 years at diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.04.010DOI Listing

Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort.

Breast 2020 Apr 23;52:50-57. Epub 2020 Apr 23.

Institut Curie, Paris-Saint Cloud, 26, Rue d'Ulm, 75005, Paris, France. Electronic address:

Background: Young age is a poor prognostic factor in early stage breast cancer (BC) but its value is less established in metastatic BC (MBC). We evaluated the impact of age at MBC diagnosis on overall survival (OS) across three age groups (<40, 40 to 60 and > 60 years(y)).

Methods: ESME MBC database is a national cohort, collecting retrospective data from 18 participating French cancer centers between January 01, 2008 and December 31, 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.04.009DOI Listing

Accelerated partial breast irradiation with interstitial multicatheter brachytherapy after breast-conserving surgery for low-risk early breast cancer.

Breast 2020 Apr 22;52:45-49. Epub 2020 Apr 22.

San Roque University Hospitals, Dolores de la Rocha, 5, 35001, Las Palmas de Gran Canaria, Las Palmas, Spain; Fernando Pessoa Canarias University, Dolores dela Rocha 14, Las Palmas de Gran Canaria, Las Palmas, Spain; Fundación Canaria del Instituto Canario de Investigación del Cáncer, Avda de la Trinidad 61 Torre Agustín Arevalo 7 plantaLa Laguna, Santa Cruz de Tenerife, 38204 Spain. Electronic address:

Patients with low-risk invasive ductal carcinoma treated with breast-conserving surgery (BCS) were included in a multicatheter brachytherapy APBI protocol. The primary endpoint was ipsilateral breast recurrence. Between December 2008-December 2017, 186 low-risk breast cancer patients were treated with APBI using interstitial multicatheter brachytherapy and followed prospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.04.008DOI Listing

Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice.

Breast 2020 Apr 16;52:33-44. Epub 2020 Apr 16.

Department of Internal Medicine, Albert Schweitzer Hospital, Albert Schweitzerplaats 25, 3300 AK, Dordrecht, the Netherlands. Electronic address:

Trastuzumab prolongs progression-free and overall survival in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer. However, trastuzumab treatment is hampered by cardiotoxicity, defined as a left ventricular ejection fraction (LVEF) decline with a reported incidence ranging from 3 to 27% depending on variable factors. Early identification of patients at increased risk of trastuzumab-induced myocardial damage is of great importance to prevent deterioration to irreversible cardiotoxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.04.005DOI Listing

Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study.

Breast 2020 Apr 11;52:23-32. Epub 2020 Apr 11.

Institut Gustave Roussy, Villejuif, France. Electronic address:

Background: Evidence on how weight loss correlates to health-related quality-of-life (HRQOL) among obese breast cancer (BC) patients is limited. We aimed to evaluate associations between weight changes and HRQOL.

Methods: We included 993 obese women with stage I-II-III BC from CANTO, a multicenter, prospective cohort collecting longitudinal, objectively-assessed anthropometric measures and HRQOL data (NCT01993498). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.04.002DOI Listing
April 2020
2.381 Impact Factor

Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers.

Breast 2020 Apr 16;52:17-22. Epub 2020 Apr 16.

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electronic address:

Background: We performed a retrospective study on the efficacy and safety of sirolimus (an mTOR inhibitor) in hormone receptor (HR)-positive advanced breast cancer and searched for biomarkers to predict its efficacy.

Methods: All patients with HR-positive metastatic breast cancer treated with sirolimus plus endocrine therapy between December 2017 and July 2018 at the Cancer Hospital, Chinese Academy of Medical Sciences were consecutively and retrospectively reviewed. Mutations in circulating tumour DNA (ctDNA) were assayed for 1021 tumour-related genes via gene panel target capture-based next-generation sequencing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.04.004DOI Listing

Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic.

Breast 2020 Apr 16;52:8-16. Epub 2020 Apr 16.

Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Portugal.

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) associated disease (COVID-19) outbreak seriously challenges globally all health care systems and professionals. Expert projections estimate that despite social distancing and lockdown being practiced, we have yet to feel the full impact of COVID-19. In this manuscript we provide guidance to prepare for the impact of COVID-19 pandemic on breast cancer patients and advise on how to triage, prioritize and organize diagnostic procedures, surgical, radiation and medical treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.04.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162626PMC

Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study.

Breast 2020 Apr 15;52:1-7. Epub 2020 Apr 15.

USC Oncologia, ASST Papa Giovanni XXIII, Bergamo, Italy.

Purpose: Adjuvant treatment decisions in early breast cancer (eBC) have traditionally been driven by risk stratification based on clinical and pathological risk factors. The 21-gene Oncotype DX® assay has been validated as a predictive test for benefit from adjuvant chemotherapy (CT), hence assessing its impact in clinical decisions is of high interest. The objective of this study was to estimate the rate of adjuvant treatment decision modification impacted by the Recurrence Score® result, and the consequent budget impact. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.04.003DOI Listing

Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer.

Breast 2020 Jun 23;51:120-126. Epub 2020 Mar 23.

Breast Center, St. Gallen Cantonal Hospital, Rorschacher Strasse 95, 9007, St. Gallen, Switzerland; Faculty of Medicine, University of Basel, Petersplatz 1, 4001, Basel, Switzerland.

Objectives: The proliferative activity of the Ki-67 index is important in decision-making of adjuvant treatments in early breast cancer. Its reliability can be reduced by inter-observer variability. This analysis' objective is to evaluate the robustness of Ki-67 values within one center over 5 years and to compare its distribution with a published dataset. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.03.005DOI Listing

Radiological audit of interval breast cancers: Estimation of tumour growth rates.

Breast 2020 Jun 1;51:114-119. Epub 2020 Apr 1.

Leeds Teaching Hospital NHS Trust, Beckett Street, Leeds, LS9 7TF, UK. Electronic address:

Introduction: This multicentre, retrospective study aimed to establish correlation between estimated tumour volume doubling times (TVDT) from a series of interval breast cancers with their clinicopathological features. The potential impact of delayed diagnosis on prognosis was also explored.

Materials And Methods: Interval cancers, where screening mammograms demonstrated changes that were retrospectively classified as either uncertain or suspicious, were reviewed from five screening units within the UK NHS Breast Screening Programme (NHSBSP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.03.006DOI Listing

Risk communication in a patient decision aid for radiotherapy in breast cancer: How to deal with uncertainty?

Breast 2020 Jun 6;51:105-113. Epub 2020 Apr 6.

Department of Radiation Oncology (Maastro), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, the Netherlands. Electronic address:

Background And Aim: Patient decision aids for oncological treatment options, provide information on the effect on recurrence rates and/or survival benefit, and on side-effects and/or burden of different treatment options. However, often uncertainty exists around the probability estimates for recurrence/survival and side-effects which is too relevant to be ignored. Evidence is lacking on the best way to communicate these uncertainties. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.04.001DOI Listing

Reply letter to Leong LT.

Breast 2020 Jun 31;51:103-104. Epub 2020 Mar 31.

Institute of Radiology, Department of Medicine, University of Udine, University Hospital S. Maria Della Misericordia, P.le S. Maria Della Misericordia, 15, 33100, Udine, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.03.008DOI Listing

Correspondence: Preoperative assessment of breast cancer: Multireader comparison of contrast-enhanced MRI versus the combination of unenhanced MRI and digital breast tomosynthesis.

Authors:
Lambert T Leong

Breast 2020 Jun 31;51:102. Epub 2020 Mar 31.

Department of Molecular Bioscience and Bioengineering, University of Hawaii at Manoa, 2500 Campus Rd, Honolulu, HI, 96822, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.03.007DOI Listing

What are the appropriate thresholds for High Quality Performance Indicators for breast surgery in Australia and New Zealand?

Breast 2020 Jun 30;51:94-101. Epub 2020 Jan 30.

University of Sydney, Royal North Shore Hospital Sydney, Australia; Surgical Oncology at the Poche Centre, Suite 2, 40 Rocklands Rd, North Sydney, NSW, 2060, Australia. Electronic address:

Aim: To evaluate BreastSurgANZ members' compliance at various threshold rates for 4 evaluable High-Quality Performance Indicators (HQPIs) introduced to improve patient care. To benchmark global best practice to assist in determining the eventual threshold standards.

Method: BreastSurgANZ Quality Audit data 2012-2016 & 2018 was used to determine rates of attainment through a range of thresholds for 4 HQPI's. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.01.007DOI Listing

Reduced symptom burden with the support of an interactive app during neoadjuvant chemotherapy for breast cancer - A randomized controlled trial.

Breast 2020 Jun 20;51:85-93. Epub 2020 Mar 20.

Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Nursing, Stockholm, Sweden.

Objectives: Neoadjuvant chemotherapy causes distressing symptoms, which have to be managed by patients at home. Assessing and acting upon relevant patient-reported symptoms regularly with the support of mHealth such as apps, has shown to decrease symptom burden and improve health-related quality of life (HRQoL). There is a lack of apps for patients with breast cancer which are tested in rigorous trials and only a few include interactive components for immediate clinical management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.03.004DOI Listing

The requirements of a specialist breast centre.

Breast 2020 Jun 26;51:65-84. Epub 2020 Feb 26.

Iridium Kankernetwerk, University of Antwerp, Faculty of Medicine and Health Sciences, Campus Drie Eiken, Wilrijk-Antwerp, Belgium.

This article is an update of the requirements of a specialist breast centre, produced by EUSOMA and endorsed by ECCO as part of Essential Requirements for Quality Cancer Care (ERQCC) programme, and ESMO. To meet aspirations for comprehensive cancer control, healthcare organisations must consider the requirements in this article, paying particular attention to multidisciplinarity and patient-centred pathways from diagnosis, to treatment, to survivorship. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.02.003DOI Listing

Health state utilities for metastatic breast cancer in Taiwan.

Breast 2020 Jun 6;51:57-64. Epub 2020 Mar 6.

Department of Clinical Pharmacy, School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan; Research Center of Pharmacoeconomics, College of Pharmacy, Taipei Medical University, Taipei, Taiwan. Electronic address:

Background: New developments in medications for metastatic breast cancer (MBC) can be of great benefit to patients, but unfortunately these medicines also increase expenditures. Cost-utility analyses (CUAs) are needed to allocate health resources properly, and health utility values are required to calculate quality-adjusted life years in those CUAs.

Objective: The aims of this study were to measure health utility values for several MBC-related health states and certain breast cancer treatment-related grade 3/4 adverse drug reactions (ADRs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.03.001DOI Listing

The effect of post mastectomy radiation therapy on survival in breast cancer patients with N1mic disease.

Breast 2020 Jun 6;51:50-56. Epub 2020 Mar 6.

Department of Radiation Oncology, Rush University Medical Center, Chicago, IL, 60612, USA. Electronic address:

Background: The role of post mastectomy radiation therapy (PMRT) in patients with N1mic breast cancer has not been well defined. A retrospective analysis was performed using the SEER database to evaluate the impact of PMRT on survival in patients with N1mic breast cancer.

Materials And Methods: Women with T1-T2, N1mic, M0 breast cancer who had undergone mastectomy were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.02.009DOI Listing

The survival benefit of postmastectomy radiotherapy for breast cancer patients with T1-2N1 disease according to molecular subtype.

Breast 2020 Jun 12;51:40-49. Epub 2020 Mar 12.

Department of Breast Surgery, Fudan University Shanghai Cancer Center, Cancer Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, PR China. Electronic address:

Objective: To evaluate the significance of postmastectomy radiotherapy (PMRT) in female breast cancer patients with T1-2N1M0 disease according to molecular subtypes and other risk factors.

Method: We conducted a retrospective cohort-based study utilizing the Surveillance, Epidemiology, and End Results database. Patients who were diagnosed with T1-2N1M0 invasive breast cancer and received mastectomy between 2010 and 2014 were enrolled in our study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.03.003DOI Listing

Dual HER2 blockade in the first-line treatment of metastatic breast cancer - A retrospective population-based observational study in Danish patients.

Breast 2020 Jun 13;51:34-39. Epub 2020 Mar 13.

Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark.

Objectives: Randomized clinical trials do not include a population that truly reflects a real-world population, due to their inclusion and exclusion criteria. This leads to concerns about the applicability of these studies in a clinical practice. In the present study, we aim to describe the clinical and demographic characteristics, treatment patterns, and clinical outcomes in a population of patients with HER2-positive metastatic breast cancer who received pertuzumab and trastuzumab as first-line treatment in a real-world setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.03.002DOI Listing

Evaluation of 2014 margin guidelines on re-excision and recurrence rates after breast conserving surgery: A multi-institution retrospective study.

Breast 2020 Jun 6;51:29-33. Epub 2020 Mar 6.

Comprehensive Breast Program, Moffitt Cancer Center Tampa, FL, USA. Electronic address:

Introduction: A 2014 consensus statement from the Society of Surgical Oncology and American Society for Radiation Oncology supported "no ink on tumor" as an adequate margin for breast conserving therapy (BCT). This study evaluates this statement in a multi-institution cohort.

Methods: A retrospective review of BCT cases at 3 comprehensive cancer centers was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.02.013DOI Listing

Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study.

Breast 2020 Jun 3;51:21-28. Epub 2020 Mar 3.

Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, 428 Church St, 48109, Ann Arbor, MI, USA.

Purpose: Discrepancies between clinicians' assessment of chemotherapy-induced peripheral neuropathy (CIPN) and patient-reported outcomes (PRO) have been described, though the underlying reasons are unknown. Our objective was to identify potential patient-specific factors associated with under-describing of CIPN to clinicians in women with non-metastatic breast cancer treated with paclitaxel.

Methods: Patients enrolled in an observational study (n = 60) completed weekly CIPN PRO using the EORTC CIPN20. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.02.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198332PMC

Evaluation of the 8th edition of the American joint committee on cancer's pathological staging system in prognosis assessment and treatment decision making for stage T1-2N1 breast cancer after mastectomy.

Breast 2020 Jun 3;51:2-10. Epub 2020 Mar 3.

Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, 651 Dongfeng Road East, Guangzhou, 510060, PR China. Electronic address:

Purpose: The 8th edition of the American Joint Committee on Cancer (AJCC) pathological staging system for breast cancer considers biologic factors in addition to the anatomical features included in the previous systems. The purpose of this study was to determine the validity of the 8th AJCC staging system for T1-2N1 breast cancer and to assess the effect of additional chemotherapy and radiotherapy according to the new pathologic stages.

Methods: The cohort included patients from the Surveillance, Epidemiology, and End Results program (2010-2012) who had stage T1-2N1 invasive breast carcinoma and underwent mastectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.02.012DOI Listing

Prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in breast: A meta-analysis of PSM studies.

Breast 2020 Jun 29;51:11-20. Epub 2020 Jan 29.

Department of Breast Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China. Electronic address:

Background: Invasive micropapillary carcinoma (IMPC) is a rare histological subtype of breast cancer. The outcome of IMPC remains controversial; we conducted a meta-analysis of propensity score matching (PSM) studies to evaluate the prognostic difference between IMPC and invasive ductal carcinoma (IDC).

Methods: We searched PubMed, EMBASE and the Cochrane library for PSM studies comparing survival data between IMPC and IDC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.01.041DOI Listing

Comment on: "Multidisciplinary team meeting and EUSOMA quality indicators in breast cancer care: A French regional multicenter study".

Breast 2020 Jun 4;51. Epub 2020 Mar 4.

Division of Radiation Oncology, Institute of Oncology Ljubljana, Zaloska Cesta 2, Ljubljana, Slovenia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.02.010DOI Listing

Clinical outcome of patients with brain metastases from breast cancer - A population based study over 21 years.

Breast 2020 Apr 20;50:113-124. Epub 2020 Feb 20.

Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. Electronic address:

Background: Brain metastases (BM) are a feared progression of breast cancer (BC) with impact on quality of life and survival. Despite improved treatments, it is believed patients suffering from BM are increasing.

Aims: To study potential changes in the number of BM, the possible links between BC subgroup and extent of BM with prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.02.007DOI Listing

Breast cancer risk, worry, and anxiety: Effect on patient perceptions of false-positive screening results.

Breast 2020 Apr 13;50:104-112. Epub 2020 Feb 13.

Mongan Institute Health Policy Center, Massachusetts General Hospital, Boston, MA, USA.

Objective: The impact of mammography screening recall on quality-of-life (QOL) has been studied in women at average risk for breast cancer, but it is unknown whether these effects differ by breast cancer risk level. We used a vignette-based survey to evaluate how women across the spectrum of breast cancer risk perceive the experience of screening recall.

Methods: Women participating in mammography or breast MRI screening were recruited to complete a vignette-based survey. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.02.004DOI Listing

The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review.

Breast 2020 Apr 19;50:95-103. Epub 2020 Feb 19.

Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.

Objective: The majority of 'low-risk' (grade I/II) Ductal Carcinoma In Situ (DCIS) may not progress to invasive breast cancer during a women's lifetime. Therefore, the safety of active surveillance versus standard surgical treatment for DCIS is prospectively being evaluated in clinical trials. If proven safe and selectively implemented in clinical practice, a significant group of women with low-risk DCIS may forego surgery and radiotherapy in the future. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.02.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073883PMC

"Three-dimensional evaluation of breast volume changes following autologous free flap breast reconstruction over six months".

Breast 2020 Apr 10;50:85-94. Epub 2020 Feb 10.

Department of Plastic and Reconstructive Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.

Objectives: To date, little is known about postoperative changes in breast volume after autologous breast reconstruction. The purpose of this retrospective study was to investigate breast volume changes following autologous free flap reconstruction and the factors affecting flap volume.

Materials And Methods: Patients who underwent deep inferior epigastric perforator, superficial inferior epigastric artery and profunda artery perforator flaps between December 2016 and January 2019 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.02.005DOI Listing

Evaluation of existing patient educational materials and development of a brochure for women with dense breasts.

Breast 2020 Apr 5;50:81-84. Epub 2020 Feb 5.

Chronic Disease Division, Boston Public Health Commission, Boston, MA, USA.

Objectives: In this pilot study, we developed and assessed acceptability of a brochure for women with dense breasts.

Material And Methods: We measured Flesch-Kincaid Readability of 22 existing breast density educational materials. We then developed a brochure and tested it in two populations of women: 44 safety net hospital patients and 13 Breast Cancer Surveillance Consortium stakeholders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.02.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110420PMC

Machine-learned identification of psychological subgroups with relation to pain interference in patients after breast cancer treatments.

Breast 2020 Apr 7;50:71-80. Epub 2020 Feb 7.

Institute of Clinical Pharmacology, Goethe - University, Theodor - Stern - Kai 7, 60590, Frankfurt Am Main, Germany; Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Theodor - Stern - Kai 7, 60590, Frankfurt Am Main, Germany. Electronic address:

Background: Persistent pain in breast cancer survivors is common. Psychological and sleep-related factors modulate perception, interpretation and coping with pain and may contribute to the clinical phenotype. The present analysis pursued the hypothesis that breast cancer survivors form subgroups, based on psychological and sleep-related parameters that are relevant to the impact of pain on the patients' life. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.01.042DOI Listing

Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.

Breast 2020 Apr 31;50:64-70. Epub 2020 Jan 31.

Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Electronic address:

Background: STEPAUT, an Austrian non-interventional study, evaluated the safety and efficacy of everolimus plus exemestane in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) recurring/progressing on/after nonsteroidal aromatase inhibitors (NSAIs) in routine clinical practice.

Methods: Postmenopausal women with HR+, HER2- ABC progressing on/after NSAIs receiving everolimus plus exemestane in accordance with routine practice and the current version of Summary of Product Characteristics were eligible. Planned individual observation period corresponded to the duration of treatment until formal study end. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.01.035DOI Listing
April 2020
2.381 Impact Factor

Study validity depends on the study design and bias. Comment on "Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia" by Bajpai et al. (The Breast. 2019 December 12. Doi: 10.1016/j.breast.2019.12.004 [Epub ahead of print]).

Authors:
Ashwin Patel

Breast 2020 04 30;50:149. Epub 2020 Jan 30.

Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, Texas 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.01.040DOI Listing

Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model.

Breast 2020 Apr 27;50:56-63. Epub 2020 Jan 27.

Oncologia Medica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica Del Sacro Cuore, Roma, Italy. Electronic address:

Introduction: The clinico-pathological and molecular factors that drive the prognosis of invasive lobular breast carcinoma (ILC) are not entirely explored. In this regard, the development and validation of a prognostic model for ILC and the investigation of the distribution of molecular abnormalities (focusing on CDK4/6 alterations) according to prognosis were the aims of this study.

Patients And Methods: Two clinico-pathological multi-center data-sets of early-stage ILC patients (Training/Validation Set, TS/VS) were gathered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.01.034DOI Listing

Using artificial intelligence to analyse and teach communication in healthcare.

Breast 2020 Apr 17;50:49-55. Epub 2020 Jan 17.

University of Rochester, Rochester Human-Computer Interaction Group, Rochester, New York, USA.

Communication is a core component of effective healthcare that impacts many patient and doctor outcomes, yet is complex and challenging to both analyse and teach. Human-based coding and audit systems are time-intensive and costly; thus, there is considerable interest in the application of artificial intelligence to this topic, through machine learning using both supervised and unsupervised learning algorithms. In this article we introduce health communication, its importance for patient and health professional outcomes, and the need for rigorous empirical data to support this field. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.01.008DOI Listing

3D digital breast cancer models with multimodal fusion algorithms.

Breast 2020 Feb 3;49:281-290. Epub 2020 Jan 3.

INESC TEC, Portugal; Champalimaud Foundation, Portugal; Nova Medical School, Portugal.

Breast cancer image fusion consists of registering and visualizing different sets of a patient synchronized torso and radiological images into a 3D model. Breast spatial interpretation and visualization by the treating physician can be augmented with a patient-specific digital breast model that integrates radiological images. But the absence of a ground truth for a good correlation between surface and radiological information has impaired the development of potential clinical applications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.12.016DOI Listing
February 2020

When to assess the flap perfusion by introperative indocyanine green angiography(ICGA): On the donor site or the recipient site?

Breast 2020 Jan 8. Epub 2020 Jan 8.

Plastic Surgery Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.01.002DOI Listing
January 2020

Invasive breast cancer over four decades reveals persisting poor metastatic outcomes in treatment resistant subgroup - the "ATRESS" phenomenon.

Breast 2020 Apr 14;50:39-48. Epub 2020 Jan 14.

School of Cancer & Pharmaceutical Sciences, King's College London, Great Maze Pond, London, SE1 9RT, United Kingdom; Guy's and St Thomas NHS Foundation Trust, Great Maze Pond, London, SE1 9RT, United Kingdom. Electronic address:

Background: Major advances in breast cancer treatment have led to a reducuction in mortality. However, there are still women who are not cured. We hypothesize there is a sub-group of women with treatment-resistant cancers causing early death. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.01.006DOI Listing

A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients.

Breast 2020 Apr 14;50:30-38. Epub 2020 Jan 14.

Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.

Objectives: Chemotherapy-induced nausea and vomiting (CINV) are distressing symptoms. This randomized study evaluated the antiemetic efficacies of standard antiemetic regimen with/without olanzapine.

Patients And Methods: Eligible patients were chemotherapy-naive Chinese breast cancer patients who were planned for (neo)adjuvant doxorubicin/cyclophosphamide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.01.005DOI Listing

Improving breast cancer care coordination and symptom management by using AI driven predictive toolkits.

Breast 2020 Apr 21;50:25-29. Epub 2020 Jan 21.

UM-AI Coordinator Research, UM-AI LLC, 8 the Green. Suite #5064, Dover, DE, 19901, USA. Electronic address:

Integrated breast cancer care is complex, marked by multiple hand-offs between primary care and specialists over an extensive period of time. Communication is essential for treatment compliance, lowering error and complication risk, as well as handling co-morbidity. The director role of care, however, becomes often unclear, and patients remain lost across departments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.12.006DOI Listing

Automatic detection of perforators for microsurgical reconstruction.

Breast 2020 Apr 12;50:19-24. Epub 2020 Jan 12.

Breast Unit, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal; Faculdade de Medicina da Universidade Nova de Lisboa, Nova Medical School, Lisbon, Portugal.

The deep inferior epigastric perforator (DIEP) is the most commonly used free flap in mastectomy reconstruction. Preoperative imaging techniques are routinely used to detect location, diameter and course of perforators, with direct intervention from the imaging team, who subsequently draw a chart that will help surgeons choosing the best vascular support for the reconstruction. In this work, the feasibility of using a computer software to support the preoperative planning of 40 patients proposed for breast reconstruction with a DIEP flap is evaluated for the first time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.01.001DOI Listing

Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients.

Breast 2020 Apr 8;50:11-18. Epub 2020 Jan 8.

Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.

Background: Patients with breast cancer (BC) show strong interest in complementary and alternative medicine (CAM), particularly for adverse effects of adjuvant endocrine treatment - e.g., with letrozole. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.12.017DOI Listing

Teaching cross-cultural design thinking for healthcare.

Breast 2020 Apr 6;50:1-10. Epub 2020 Jan 6.

Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA; Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

Objectives: Artificial intelligence (AI) is poised to transform breast cancer care. However, most scientists, engineers, and clinicians are not prepared to contribute to the AI revolution in healthcare. In this paper, we describe our experiences teaching a new undergraduate course for American students that aims to prepare the next generation for cross-cultural designthinking, which we believe is crucial for AI to achieve its full potential in breast cancer care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.12.015DOI Listing

Second conservative treatment for second ipsilateral breast tumor event: A systematic review of the different re-irradiation techniques.

Breast 2020 Feb 9;49:274-280. Epub 2020 Jan 9.

Department of Radiation Oncology, Antoine Lacassagne Cancer Center, University of Cote D'Azur, Nice, France. Electronic address:

Aim: To address the different partial breast re-irradiation techniques available in the context of second conservative treatment (SCT), as an alternative to salvage mastectomy, for 2nd ipsilateral breast tumor event (IBTE) and summarize their respective oncological and toxicity outcomes.

Material And Methods: A literature search was made based on MeSH/PubMed, including papers from 1995 to 2019. Each article was described according to the main irradiation technique, fractionation, oncological results and grade 3 toxicities related to the salvage conservative treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.01.003DOI Listing
February 2020

Artificial intelligence in digital breast pathology: Techniques and applications.

Breast 2020 Feb 19;49:267-273. Epub 2019 Dec 19.

Department of Histopathology, Division of Cancer and Stem Cells, School of Medicine, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, NG5 1PB, UK. Electronic address:

Breast cancer is the most common cancer and second leading cause of cancer-related death worldwide. The mainstay of breast cancer workup is histopathological diagnosis - which guides therapy and prognosis. However, emerging knowledge about the complex nature of cancer and the availability of tailored therapies have exposed opportunities for improvements in diagnostic precision. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.12.007DOI Listing
February 2020